SC11: DEVELOPABILITY OF BISPECIFIC ANTIBODIES: FORMATS AND APPLICATIONS

TUESDAY, APRIL 9 | 6:00 - 8:30 PM (Federal Complex)

ABOUT THIS COURSE:

Bispecific antibodies are a rapidly growing and clinically validated class of antibodies with three marketed drugs and multiple candidates in clinical trials. Targeting multiple antigens in a synergistic manner can confer enhanced therapeutic benefit and potentially uncover novel biological mechanisms. However, multiple formats and a tedious candidate selection process to select functional and developable bispecific antibodies makes such programs fairly cumbersome. This short course highlights the rapid growth in the field, therapeutic applications and focuses on challenges with discovery and development of bispecific antibodies. We will use an approved bispecific antibody as a case study to understand the varied aspects of discovery and development of bispecific antibody programs.

WHAT YOU WILL LEARN:

• Introduction to bispecifics and bispecific formats
• Therapeutic applications of bispecific antibodies
• Developability of bispecifics
• Case study: Discovery and development of an FDA approved bispecific antibody

INSTRUCTOR BIOGRAPHY:

Nimish Gera, PhD, Director, Research and Development, Mythic Therapeutics

Nimish Gera is the Director of Research and Development at Mythic Therapeutics leading multiple projects to engineer and develop novel antibody and antibody-based drugs in oncology and immuno-oncology. Prior to Mythic, Nimish has over ten years of experience in antibody and protein engineering with five years leading bispecific antibody programs in several disease areas such as rare diseases, oncology and immunology at Alexion Pharmaceuticals and Oncobiologics. Nimish received his PhD degree in Chemical and Biomolecular Engineering from North Carolina State University and a B.Tech degree in Chemical Engineering from Indian Institute of Technology, Guwahati.